Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for milestone payments under existing collaboration Scott ...
Vividion publishes manuscript detailing the discovery and optimization of VVD-214, the company’s covalent inhibitor of WRN.
New research reveals that certain brain tumors may originate silently within normal brain cells long before a tumor forms.
SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage ...
Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and ...
Artificial intelligence (AI) is transforming the life sciences industry, with potentially its most significant impact on drug ...
Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce ...
When war breaks out, power plants are attacked first along with military facilities like air defense networks. The same thing happens in the war inside the human body. Cancer cells have been found to ...
AZoLifeSciences on MSN
Study overturns understanding about how T cells recognize lipid antigens
A new discovery about how cells communicate with each other in the body's immune system has revealed deeper insights for an ...
SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results